Bristol-Myers Squibb is poised to announce its fourth-quarter results next month, and analysts predict a single-digit decline ...
Bristol-Myers Squibb Company (NYSE:BMY) is one of the cheap stocks to buy for the next 3 years. On January 9, Scotiabank ...
The Delhi High Court has allowed Zydus Lifesciences to sell its nivolumab biosimilar, citing public interest, while directing ...
CHENNAI: A division bench of the Delhi High Court on Monday allowed Indian drugmaker Zydus Lifesciences to sell and market ...
MedPage Today on MSN
Regimen improves PFS in highly mutated metastatic colorectal cancer
Accrual in this trial was suspended in March 2025 as a result of findings from the Checkmate 8HW trial, which showed that the ...
Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.
As someone who's followed the evolution of cancer treatments closely—both personally, having supported loved ones through their battles, and professionally in the pharmaceutical space—I've been ...
Also highlight plans to integrated with Biocon at 44th Annual J.P. Morgan Healthcare Conference in San Francisco ...
Biocon Biologics is set to unveil three new biosimilar oncology assets — Trastuzumab/Hyaluronidase (Herceptin SC/Herceptin HYLECTA), Nivolumab (Opdivo), and Pembrolizumab (Keytruda) — at the 2026 JP ...
He will also participate in a fireside chat at the ENDPOINTS at JPM26 conference on Tuesday, January 13 titled, "Achieving ...
The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to novel therapies. In this overview, PharmTech takes a look back at significant ...
The U.S. Food and Drug Administration (FDA) on Tuesday approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment of adult and pediatric ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback